Insights

Gathering insights about Mend…

Similar companies to Mend

Mend Tech Stack

Mend uses 8 technology products and services including Google Optimize, Adobe, Canva, and more. Explore Mend's tech stack below.

Google Optimize
A/B Testing
Adobe
Audio, Video, Graphics
Canva
Audio, Video, Graphics
Jenkins
Continuous Integration
Google Cloud Platform
Infrastructure As A Service
Atlassian Jira
Issue Trackers
RankMath SEO
Web Platform Extensions
Nginx
Web Servers

Media & News

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonate Superior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions , including whole brain Faster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs.
Mar 26, 2026 | www.prnewswire.com
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patients Topline data expected in third quarter of 2026 Topline data from the clinically completed "lithium in brain" imaging study in healthy subjects expected by the end of March 2026 ATLANTA, March 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the initiation of its Phase II clinical trial evaluating AL001 in patients diagnosed with BD type 1. The trial is being conducted at Massachusetts General Hospital ("MGH") and represents a significant step toward advancement of AL001 as a potentially safer and more effective lithium-based therapy.
Mar 16, 2026 | www.prnewswire.com
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?
Shares of Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) dropped 2.5% on Monday. The stock traded as low as $2.20 and last traded at $2.33. Approximately 43,364 shares were traded during mid-day trading, a decline of 21% from the average daily volume of 55,007 shares. The stock had previously closed at $2.39. Wall
Jan 13, 2026 | www.defenseworld.net
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why
Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) shares were down 0.5% on Friday. The company traded as low as $1.95 and last traded at $1.96. Approximately 72,560 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 143,648 shares. The stock had previously closed at $1.97. Analysts
Nov 22, 2025 | www.defenseworld.net
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA , Nov. 19, 2025 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects. In collaboration with Massachusetts General Hospital as the clinical trial site, Alzamend is investigating the distinctive characteristics of AL001.
Nov 19, 2025 | www.prnewswire.com
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced it will have a poster presentation at the Military Health System Research Symposium (“MHSRS”), being held from August 4-7, 2025, in Orlando, Florida. “Our upcoming poster presentation at MHSRS 2025 represents an exceptional opportunity to spotlight our cutting-edge innovation and its transformative potential for active-duty service members and military veterans,” said Stephan Jackman, Chief Executive Officer of Alzamend.
Jul 28, 2025 | www.globenewswire.com
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alzamend dosed the first patient for the healthy human patients for the AL001 “Lithium in Brain” Studies at Massachusetts General Hospital In June 2025, Alzamend completed the final closing of its $5 million private placement months ahead of schedule ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with the Securities and Exchange Commission. Alzamend has strengthened its financial position, reflecting a strategic focus on fiscal prudence and effective capital management.
Jul 23, 2025 | www.globenewswire.com

Mend's Email Address Formats

Mend uses at least 2 format(s):

Mend Email Formats	Example	Percentage
First.Last@whitesourcesoftware.com	John.Doe@whitesourcesoftware.com	87%
First@whitesourcesoftware.com	John@whitesourcesoftware.com	6%
Last@whitesourcesoftware.com	Doe@whitesourcesoftware.com	3%
FLast@whitesourcesoftware.com	JDoe@whitesourcesoftware.com	1%
First.Middle@whitesourcesoftware.com	John.Michael@whitesourcesoftware.com	1%
FL@whitesourcesoftware.com	JD@whitesourcesoftware.com	1%
First.L@whitesourcesoftware.com	John.D@whitesourcesoftware.com	1%
First.Last@mend.io	John.Doe@mend.io	99%
First.MiddleLast@mend.io	John.MichaelDoe@mend.io	1%

Frequently Asked Questions

Where is Mend's headquarters located?

Mend's main headquarters is located at 33 Arch Street Suite 1700 Boston, Massachusetts 02110 United States. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is Mend's stock symbol?

Mend is a publicly traded company; the company's stock symbol is ALZN.

What is Mend's official website and social media links?

Mend's official website is mend.io and has social profiles on LinkedIn Crunchbase.

What is Mend's NAICS code?

Mend's NAICS code is 5112 - Software Publishers.

How many employees does Mend have currently?

As of March 2026, Mend has approximately 267 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Ceo And Co-Founder: A. C.Chief Financial Officer: I. S.Chief Of Staff To The Ceo And Ai Initiatives Leader: I. S. Z.. Explore Mend's employee directory with LeadIQ.

What industry does Mend belong to?

Mend operates in the Software Development industry.

What technology does Mend use?

Mend's tech stack includes Google OptimizeAdobeCanvaJenkinsGoogle Cloud PlatformAtlassian JiraRankMath SEONginx.

What is Mend's email format?

Mend's email format typically follows the pattern of First.Last@whitesourcesoftware.com. Find more Mend email formats with LeadIQ.

When was Mend founded?

Mend was founded in 2011.

Mend

Q: What is Mend's official website and social media links?

Mend's official website is mend.io. Mend has social profiles on LinkedIn.

Q: How many employees does Mend have currently?

Mend has approximately 267 employees.

Q: What technology does Mend use?

Mend's tech stack includes TeamCity, Atlassian Jira, NetSuite, LinkedIn, ReportPortal.

Software DevelopmentMassachusetts, United States201-500 Employees

Meet the AI native AppSec platform built for enterprise scale
At Mend.io, we believe security should empower, not block.
Our mission is to make application security frictionless for developers and scalable for security teams without compromise.

Company Overview

Headquarters: 33 Arch Street Suite 1700 Boston, Massachusetts 02110 United States
Website: mend.io
Stock Symbol: ALZN
NAICS Code: 5112 - Software Publishers
Founded: 2011
Employees: 201-500

Media & News

Funding & Financials

$100M$250M
Mend's revenue is estimated to be in the range of $100M$250M

Funding & Financials

$100M$250M
Mend's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Mend

GitHub

Qualys

Twistlock

JFrog

Snyk

Sonatype

Tenable

Veracode

GitLab

Aqua Security

Checkmarx

Rapid7

Mend Tech Stack

Media & News

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?

Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Mend's Email Address Formats

Frequently Asked Questions

Where is Mend's headquarters located?

What is Mend's stock symbol?

What is Mend's official website and social media links?

What is Mend's NAICS code?

How many employees does Mend have currently?

What industry does Mend belong to?

What technology does Mend use?

What is Mend's email format?

When was Mend founded?

Mend

Company Overview

Media & News

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell?

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?